Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma.StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.

Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep. 2017;9(1):6887.

Article  PubMed  PubMed Central  Google Scholar 

Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–7.

Article  PubMed  PubMed Central  Google Scholar 

Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1). https://doi.org/10.3390/medsci9010003.

Rögnvaldsson S, Thorsteinsdóttir S, Kristinsson SY. Screening in Multiple Myeloma and Its Precursors: Are We There Yet? Clin Chem. 2024;70(1):128–39.

Article  PubMed  Google Scholar 

Soekojo CY, De Mel S, Ooi M, Yan B, Chng WJ. Potential clinical application of genomics in multiple myeloma. Int J Mol Sci. 2018;19(6):1721.

Article  PubMed  PubMed Central  Google Scholar 

Banu C, Moise A, Arion C, Coriu D, T̆nase A, Constantinescu I. Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life. 2011;4(3):264.

Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, et al. Insulin-like growth factor-1-and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomark Prev. 2009;18(1):282–8.

Article  CAS  Google Scholar 

Aghaei M, Khademi R, Far MAJ, Bahreiny SS, Mahdizade AH, Amirrajab N. Genetic Variants of Dectin-1 and their antifungal immunity impact in Hematologic Malignancies: A Comprehensive Systematic Review. Curr Res Trans Med. 2024:103460.

Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(Suppl 1):S3-s25.

CAS  PubMed  Google Scholar 

Derudas D, Capraro F, Martinelli G, Cerchione C. How I manage frontline transplant-ineligible multiple myeloma. Hematol Rep. 2020;12(Suppl 1):8956.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordan LN, Marks SM, Xue M, Nagovski N, Lambert JH, Smith RE. Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting. Future Oncol. 2022;18(3):301–9.

Article  CAS  PubMed  Google Scholar 

Kumar SK, Callander NS, Adekola K, Anderson LD, Jr., Baljevic M, Baz R, et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(12):1281–301.

Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang A, et al. The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009;43(7):539–45.

Article  CAS  PubMed  Google Scholar 

Aghapour SA, Torabizadeh M, Bahreiny SS, Saki N, Jalali Far MA, Yousefi-Avarvand A, et al. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review. Iran J Blood Cancer. 2024;16(2):84–101.

Article  Google Scholar 

Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol. 2012;88(2):93–117.

Article  CAS  PubMed  Google Scholar 

Mahdizade AH, Bahreiny SS, Bastani M-N, Dabbagh MR, Aghaei M, Ali Malayeri F, et al. The influence of CDKAL1 (rs7754840) gene polymorphism on susceptibility to gestational diabetes mellitus in pregnant women: a systematic review and meta-analysis. Int J Diabetes Dev Countries. 2023. https://doi.org/10.1007/s13410-023-01272-7.

Saki N, Haybar H, Aghaei M. Subject: Motivation can be suppressed, but scientific ability cannot and should not be ignored. J Transl Med. 2023;21(1):520.

Article  PubMed  PubMed Central  Google Scholar 

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 2012;131(5):E636–42.

Article  CAS  PubMed  Google Scholar 

Kaushik S, Kaushik S, Sharma D. Functional Genomics. In: Ranganathan S, Gribskov M, Nakai K, Schönbach C, editors. Encyclopedia of Bioinformatics and Computational Biology. Oxford: Academic Press; 2019. p. 118–33.

Chapter  Google Scholar 

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98.

Article  CAS  PubMed  Google Scholar 

Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, et al. US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559–63.

Article  CAS  PubMed  Google Scholar 

Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou S-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7–8):802–32.

Article  CAS  PubMed  Google Scholar 

Obata H, Yahata T, Quan J, Sekine M, Tanaka K. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res. 2006;26(3B):2227–32.

CAS  PubMed  Google Scholar 

Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, Zhou H-H, Liu Z-Q. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics. 2009;19(3):206–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010;89:1133–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24(1):65–97.

Article  CAS  PubMed  Google Scholar 

Kouki T, Sawai Y, Gardine CA, Fisfalen M-E, Alegre M-L, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol. 2000;165(11):6606–11.

Article  CAS  PubMed  Google Scholar 

Mäurer M, Loserth S, Kolb-Mäurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+ 49) alters T-cell activation. Immunogenetics. 2002;54:1–8.

Article  PubMed  Google Scholar 

Ligers A, Teleshova N, Masterman T, Huang W, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2(3):145–52.

Article  CAS  PubMed  Google Scholar 

Wang X, Zhao X, Giscombe R, Lefvert A. A CTLA-4 gene polymorphism at position− 318 in the promoter region affects the expression of protein. Genes Immun. 2002;3(4):233–4.

Article  PubMed  Google Scholar 

Qin X-Y, Lu J, Li G-X, Wen L, Liu Y, Xu L-P, et al. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Ann Hematol. 2018;97(3):485–95.

Article  CAS  PubMed  Google Scholar 

Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Péguet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J, Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol. 1994;24(4):884–91.

Article  PubMed  Google Scholar 

Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol. 1992;148(4):1143–8.

Article  CAS  PubMed